Mazdutide
Also known as: IBI362, LY3305677
Mazdutide is an investigational dual GLP-1 and glucagon receptor agonist being studied for weight management and metabolic conditions. It is not an approved medicine.
- Category
- Metabolic / GLP-1
- Reported half-life
- Reported to support weekly dosing in trials; not fully established
- Common forms
- Investigational injectable (clinical-trial setting), Research-grade vials (not approved)
- Research status
- Investigational GLP-1/glucagon dual agonist studied in clinical trials. Not approved by the TGA or other regulators at the time of writing.
- Last updated
- 21 June 2026
Claimed effects
The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.
- Reported in trials to support weight reduction in study participants
- Reported to improve blood-glucose markers in study populations
- Reported to reduce appetite through combined gut-hormone signalling
How it is reported to work
Mazdutide is described as a dual agonist of the GLP-1 and glucagon receptors. This combination is proposed to affect appetite, glucose control and energy expenditure. These mechanisms are reported from clinical research rather than established as a marketed therapy.
Background
Mazdutide is an investigational dual agonist that engages the GLP-1 and glucagon receptors. It has been studied in clinical trials for weight management and metabolic conditions. Mazdutide is not an approved medicine. This page is educational and is not medical advice; it does not recommend use.
What the research shows
Clinical trials have reported effects on body weight and glucose markers in study participants. These are reported research findings, not established outcomes of an approved product, and results may evolve as further trials report.
| Pathway | Proposed role |
|---|---|
| GLP-1 | Appetite and glucose signalling |
| Glucagon | Energy expenditure |
What people use it for (reported)
In research discussion, mazdutide is reported to be of interest for weight and metabolic outcomes because it engages both the GLP-1 and glucagon pathways. As an investigational compound it has no approved indication anywhere. Material described online as “mazdutide” is not a verified, approved product, so its identity, purity and contents cannot be assumed, which is why independent testing is discussed in this space.
Things to be aware of
Because mazdutide is unapproved and experimental, its long-term safety is not established, and the effects reported in trials may not reflect what is sold informally. Reported effects on this page are not confirmed facts; they summarise what research and discussion describe. Anyone with metabolic health concerns should consult a qualified healthcare professional for individualised guidance. This article is educational, does not recommend any dose, and does not direct anyone to obtain or use it.
Reported positives & side effects
Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.
Reported positives
- Reported in trials to support weight reduction
- Reported to improve blood-glucose markers in study populations
- Reported strong appetite reduction via combined gut-hormone signalling
- Reported potential effects on energy expenditure from glucagon activity
Common side effects
- Reported nausea, especially during dose escalation
- Reported vomiting or diarrhoea
- Reported constipation and reduced appetite
- Reported fatigue and injection-site reactions
Rare / serious side effects
- Reported increases in heart rate in trial participants
- Theoretical pancreatitis risk shared across the GLP-class
- Reported gallbladder-related events with rapid weight loss
- Reported dehydration and electrolyte disturbance from severe GI effects
Reported misuse & overdose risks
What has been reported to happen with overuse, excessive dosing, or long-term misuse of Mazdutide. Listed so you can make an informed decision, not to suggest any use is safe.
- Because it is investigational, self-dosing outside trials is reported to risk severe dehydration and electrolyte loss when nausea and vomiting go unmanaged.
- Skipping gradual dose escalation is reported to provoke intense GI effects and reports of muscle loss from inadequate intake.
- Overuse for rapid weight loss is reported to strain the gallbladder and pancreas and raise cardiovascular concern from elevated heart rate.
- Reliance on unverified research-grade vials is reported to carry dosing-error and contamination risks given no approved formulation exists.
Reported results timeline
Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Appetite effects are reported within days, while meaningful weight changes are reported to develop over months in trial settings.
First effects
Reported appetite suppression within the first days
Noticeable change
Reported early weight and appetite changes
Clear results
Reported meaningful weight reduction in trials
Peak effect
Reported continued reduction over longer trial periods
Commonly reported dosing & protocol
Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take Mazdutide. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.
| Route | Subcutaneous injection |
|---|---|
| Typical reported dose | Investigational and NOT approved. Trial-reported doses titrated weekly into the low single-digit milligram range, e.g. roughly 3–9 mg per week |
| Frequency | Reported as once weekly in trials |
| Cycle length | Trials run over many months with stepwise dose escalation; no established consumer cycle |
Reported reconstitution (mg → units)
Illustration only: a 10 mg vial + 1 mL bacteriostatic water = 10 mg/mL. A 3 mg dose is about 0.3 mL = 30 units on a U-100 insulin syringe.
Work out the units for your vial → CalculatorReported in trials as a once-weekly injection with gradual dose escalation over many months; framed as trial-derived reporting, not advice. Mazdutide is investigational and not approved by the TGA or other regulators.
Best used with / commonly stacked with
Combinations people report using together. Reported, not recommended, stacking can increase risks.
Reported as a comparable GLP-1/glucagon dual agonist in metabolic discussion
Reported as a comparator multi-receptor agonist for weight goals
Reported as a comparator incretin agonist in weight discussion
Safety notes
Mazdutide is an experimental compound without regulatory approval, so its complete safety profile is not established. Reported effects come from controlled trials. Anyone considering metabolic treatment should consult a qualified healthcare professional; mazdutide is not an approved product in Australia.